News & Media
September 2021 - Today, we are delighted to annouce our hospital based research collaboration with Dr Nakajima (Niigata Hospital) and Dr Shigematsu (Miniami Kyoto Hospital). We are very much looking forward to working with our partners to test and validate Cortical Disarray Measurement assessment for handling real world patient MRI images to estimate dementia disease severity. Our press release is also translated in Japanese.
Japan - Research collaboration with Niigata Hospital
NEWS
More
More
6th August 2021

We recently had the honour of hosting Professor Philip Scheltens, MD, PhD as part of the Oxford Brain Diagnostics guest speaker series; he is Professor of Cognitive Neurology and director of the Alzheimer Centre Amsterdam. Professor Scheltens provided valuable insights on the pathway to precision medicine in Alzheimer’s disease, gave his thoughts on the launch of a new class of anti-amyloid drug treatments, and shared his expertise with our team in a Q&A session.
OBD Guest Speaker series - Professor Philip Scheltens
NEWS
More
28th May 2021

We recently had the honour of hosting Renaud La Joie, Assistant Professor in Residence at UCSF, as part of the Oxford Brain Diagnostics guest speaker series. Renaud shared his work showing how Alzheimer’s brain pathology and disease progression are related to various factors such as patient age of onset, clinical syndrome, and APOE. Check out the video above for a clip of the talk, and visit our YouTube channel to access the full length version.
OBD Guest Speaker series -
Ass. Professor Renaud La Joie
NEWS
More
14th May 2021

Professor Frisoni described how he and his team created a strategic roadmap for developing Alzheimer’s disease biomarkers and discussed how it could be used with Oxford Brain Diagnostics. Click the link (above) to check out the video of the talk using our YouTube channel. Watch out for more videos/discussions in the series to come.
OBD Guest Speaker series -
Professor Giovanni Frisoni
NEWS
More
Today we’re excited to announce that Oxford Brain Diagnostics has been awarded a grant of more than £1.4m by the National Institute of Health Research (NIHR) to test our technology in the NHS. We’re thrilled to conduct this multi-centre project with exceptional partners to assess Cortical Disarray Measurement’s ability to diagnose mild cognitive impairment and deliver positive health economic outcomes.
OBD wins funding to test Alzheimer’s diagnostic in NHS
NEWS
NEWS
NEWS
Japan remains a vital dementia market for Oxford Brain Diagnositics. We are very pleased to announce the JP Patent behind our Cortical Disarray Measurement (CDM®) technology has now been granted.

This news reinforces our commitment to work with the Alzheimer’s community in Japan as we move forward to establish long term partnerships and collaborations.  
Patent No.: JP6827464
GRANTED
Oxford Brain Diagnostics takes another important step towards the goal of defeating Dementia. The US Patent behind our Cortical Disarray Measurement (CDM®) technology has now been granted. Protection of our unique technology enables us to develop best in class products in the future to support the fight against Alzheimer’s and hopefully other neurological disorders.
Patent No.: US10884090
GRANTED
Thank you to INmune Bio Inc. Team -Christopher (CJ) Barnum PhD, RJ Tesi and David Moss for inviting our CEO Dr Steven Chance to XPro1595 Webinar on Expanded Phase 1b Data in Patients with Alzheimer’s Disease.

Neuroinflammation remains a very exciting and promising area of exploration in assessing the role it has to play in Alzheimer patients. We look forward to providing continued support and insights into your journey for the next phase.
XPro1595 KOL Event
21 Jan 2021 - Phase 1b Trial
NEWS
NEWS
NEWS
We are proud and very excited to announce that Oxford Brain Diagnostics has been awarded FDA Breakthrough Device Designation for our technology. This is a major step forward to support our efforts in helping clinicians, patients and pharmaceutical companies with tracking and predicting Alzheimer’s disease.
U.S. Food and Drug Administration (FDA) - Breakthrough Device Designation granted for Cortical Disarray Measurement technology.
Oxford Brain Diagnostics takes another important step towards the goal of defeating Dementia. The US Patent behind our Cortical Disarray Measurement (CDM®) technology has now been granted. Protection of our unique technology enables us to develop best in class products in the future to support the fight against Alzheimer’s and hopefully other neurological disorders.
obn Awards - Celebrating Innovation & Achievement in Life Sciences
Dr Steven Chance & Dr Mario Torso present three key results using CDM® technology - the relationship between amyloid beta accumulation and cortical architectural change, the impact of sex in whole brain cortical changes in an asymptomatic population, and the classification power of our novel cortical diffusion measurements
AAIC 2020 - Alzheimer’s Association
NEWS
NEWS
Oxford Brain Diagnostics selected as finalists by Nature Research and Merck KGaA. The Spinoff Prize celebrates excellence in original science, innovative application, and business strategy.  As a finalist, OBD and our technology, Cortical Disarray Measurement (CDM®), were featured in a recent issue of Nature.
The Nature magazine
Spinoff prize
More
More
More
More
More
More
More
More
NEWS
NEWS
April 2020 -  Oxford Brain Diagnostics has started a project for Takeda Pharmaceuticals. The Project is testing Cortical Disarray Measurement (CDM®) technology as a neurodegeneration biomarker with a view to using it in future clinical trials.
Assessing CDM® measures in grey matter micro structure in AD Patients for Takeda Pharmaceuticals
Jan 2020 - Dr Steven Chance, Chief Executive Officer, is invited back to Japan by NHO Neurology Research Group to speak on the role of CDM® as a potential clinical tool for the detection of dementia.
National Hospitals Network of Japan
Sept 2019 - Researchers hunt for new dementia detection methods.
Oxford Brain Diagnostics cited in FT Dementia supplement
NEWS
NEWS
Apr 2019 - Oxford Brain Diagnostics moves into the heart of Oxford Town centre. We are now located at Oxford Centre for Innovation.
New location
More
More
News & Media
September 2021 - Today, we are delighted to annouce our hospital based research collaboration with Dr Nakajima (Niigata Hospital) and Dr Shigematsu (Miniami Kyoto Hospital). We are very much looking forward to working with our partners to test and validate Cortical Disarray Measurement assessment for handling real world patient MRI images to estimate dementia disease severity. Our press release is also translated in Japanese.
Japan - Research collaboration with Niigata Hospital
NEWS
More
6th August 2021

We recently had the honour of hosting Professor Philip Scheltens, MD, PhD as part of the Oxford Brain Diagnostics guest speaker series; he is Professor of Cognitive Neurology and director of the Alzheimer Centre Amsterdam. Professor Scheltens provided valuable insights on the pathway to precision medicine in Alzheimer’s disease, gave his thoughts on the launch of a new class of anti-amyloid drug treatments, and shared his expertise with our team in a Q&A session.
OBD Guest Speaker series - Professor Philip Scheltens
NEWS
More
28th May 2021

We recently had the honour of hosting Renaud La Joie, Assistant Professor in Residence at UCSF, as part of the Oxford Brain Diagnostics guest speaker series. Renaud shared his work showing how Alzheimer’s brain pathology and disease progression are related to various factors such as patient age of onset, clinical syndrome, and APOE. Check out the video above for a clip of the talk, and visit our YouTube channel to access the full length version.
OBD Guest Speaker series -
Ass. Professor Renaud La Joie
NEWS
More
14th May 2021

Professor Frisoni described how he and his team created a strategic roadmap for developing Alzheimer’s disease biomarkers and discussed how it could be used with Oxford Brain Diagnostics. Click the link (above) to check out the video of the talk using our YouTube channel. Watch out for more videos/discussions in the series to come.
OBD Guest Speaker series -
Professor Giovanni Frisoni
NEWS
More
Today we’re excited to announce that Oxford Brain Diagnostics has been awarded a grant of more than £1.4m by the National Institute of Health Research (NIHR) to test our technology in the NHS. We’re thrilled to conduct this multi-centre project with exceptional partners to assess Cortical Disarray Measurement’s ability to diagnose mild cognitive impairment and deliver positive health economic outcomes.
OBD wins funding to test Alzheimer’s diagnostic in NHS
NEWS
NEWS
Japan remains a vital dementia market for Oxford Brain Diagnositics. We are very pleased to announce the JP Patent behind our Cortical Disarray Measurement (CDM®) technology has now been granted.

This news reinforces our commitment to work with the Alzheimer’s community in Japan as we move forward to establish long term partnerships and collaborations.  
Patent No.: JP6827464
GRANTED
NEWS
Oxford Brain Diagnostics takes another important step towards the goal of defeating Dementia. The US Patent behind our Cortical Disarray Measurement (CDM®) technology has now been granted. Protection of our unique technology enables us to develop best in class products in the future to support the fight against Alzheimer’s and hopefully other neurological disorders.
Patent No.: US10884090
GRANTED
Thank you to INmune Bio Inc. Team -Christopher (CJ) Barnum PhD, RJ Tesi and David Moss for inviting our CEO Dr Steven Chance to XPro1595 Webinar on Expanded Phase 1b Data in Patients with Alzheimer’s Disease.

Neuroinflammation remains a very exciting and promising area of exploration in assessing the role it has to play in Alzheimer patients. We look forward to providing continued support and insights into your journey for the next phase.
XPro1595 KOL Event
21 Jan 2021 - Phase 1b Trial
NEWS
NEWS
NEWS
We are proud and very excited to announce that Oxford Brain Diagnostics has been awarded FDA Breakthrough Device Designation for our technology. This is a major step forward to support our efforts in helping clinicians, patients and pharmaceutical companies with tracking and predicting Alzheimer’s disease.
U.S. Food and Drug Administration (FDA) - Breakthrough Device Designation granted for Cortical Disarray Measurement technology.
Oxford Brain Diagnostics takes another important step towards the goal of defeating Dementia. The US Patent behind our Cortical Disarray Measurement (CDM®) technology has now been granted. Protection of our unique technology enables us to develop best in class products in the future to support the fight against Alzheimer’s and hopefully other neurological disorders.
obn Awards - Celebrating Innovation & Achievement in Life Sciences
Dr Steven Chance & Dr Mario Torso present three key results using CDM® technology - the relationship between amyloid beta accumulation and cortical architectural change, the impact of sex in whole brain cortical changes in an asymptomatic population, and the classification power of our novel cortical diffusion measurements
AAIC 2020 - Alzheimer’s Association
NEWS
NEWS
Oxford Brain Diagnostics selected as finalists by Nature Research and Merck KGaA. The Spinoff Prize celebrates excellence in original science, innovative application, and business strategy.  As a finalist, OBD and our technology, Cortical Disarray Measurement (CDM®), were featured in a recent issue of Nature.
The Nature magazine Spinoff prize
More
More
More
More
More
More
More
More
NEWS
April 2020 -  Oxford Brain Diagnostics has started a project for Takeda Pharmaceuticals. The Project is testing Cortical Disarray Measurement (CDM®) technology as a neurodegeneration biomarker with a view to using it in future clinical trials.
Assessing CDM® measures in grey matter micro structure in AD Patients for Takeda Pharmaceuticals
More
NEWS
Jan 2020 - Dr Steven Chance, Chief Executive Officer, is invited back to Japan by NHO Neurology Research Group to speak on the role of CDM® as a potential clinical tool for the detection of dementia.
National Hospitals Network of Japan
Sept 2019 - Researchers hunt for new dementia detection methods.
Oxford Brain Diagnostics cited in FT Dementia supplement
NEWS
More
NEWS
Apr 2019 - Oxford Brain Diagnostics moves into the heart of Oxford Town centre. We are now located at Oxford Centre for Innovation.
New location
September 2021 - Today, we are delighted to annouce our hospital based research collaboration with Dr Nakajima (Niigata Hospital) and Dr Shigematsu (Miniami Kyoto Hospital). We are very much looking forward to working with our partners to test and validate Cortical Disarray Measurement assessment for handling real world patient MRI images to estimate dementia disease severity. Our press release is also translated in Japanese.
Japan - Research collaboration with Niigata Hospital
NEWS
More
News & Media
6th August 2021

We recently had the honour of hosting Professor Philip Scheltens, MD, PhD as part of the Oxford Brain Diagnostics guest speaker series; he is Professor of Cognitive Neurology and director of the Alzheimer Centre Amsterdam. Professor Scheltens provided valuable insights on the pathway to precision medicine in Alzheimer’s disease, gave his thoughts on the launch of a new class of anti-amyloid drug treatments, and shared his expertise with our team in a Q&A session.
OBD Guest Speaker series - Professor Philip Scheltens
NEWS
More
28th May 2021

We recently had the honour of hosting Renaud La Joie, Assistant Professor in Residence at UCSF, as part of the Oxford Brain Diagnostics guest speaker series. Renaud shared his work showing how Alzheimer’s brain pathology and disease progression are related to various factors such as patient age of onset, clinical syndrome, and APOE. Check out the video above for a clip of the talk, and visit our YouTube channel to access the full length version.
OBD Guest Speaker series -
Ass. Professor Renaud La Joie
NEWS
More
14th May 2021

Professor Frisoni described how he and his team created a strategic roadmap for developing Alzheimer’s disease biomarkers and discussed how it could be used with Oxford Brain Diagnostics. Click the link (above) to check out the video of the talk using our YouTube channel. Watch out for more videos/discussions in the series to come.
OBD Guest Speaker series -
Professor Giovanni Frisoni
NEWS
More
Today we’re excited to announce that Oxford Brain Diagnostics has been awarded a grant of more than £1.4m by the National Institute of Health Research (NIHR) to test our technology in the NHS. We’re thrilled to conduct this multi-centre project with exceptional partners to assess Cortical Disarray Measurement’s ability to diagnose mild cognitive impairment and deliver positive health economic outcomes.
OBD wins funding to test Alzheimer’s diagnostic in NHS
NEWS
NEWS
Japan remains a vital dementia market for Oxford Brain Diagnositics. We are very pleased to announce the JP Patent behind our Cortical Disarray Measurement (CDM®) technology has now been granted.

This news reinforces our commitment to work with the Alzheimer’s community in Japan as we move forward to establish long term partnerships and collaborations.  
Patent No.: JP6827464
GRANTED
NEWS
Oxford Brain Diagnostics takes another important step towards the goal of defeating Dementia. The US Patent behind our Cortical Disarray Measurement (CDM) technology has now been granted. Protection of our unique technology enables us to develop best in class products in the future to support the fight against Alzheimer’s and hopefully other neurological disorders.
Patent No.: US10884090
GRANTED
Thank you to INmune Bio Inc. Team -Christopher (CJ) Barnum PhD, RJ Tesi and David Moss for inviting our CEO Dr Steven Chance to XPro1595 Webinar on Expanded Phase 1b Data in Patients with Alzheimer’s Disease.

Neuroinflammation remains a very exciting and promising area of exploration in assessing the role it has to play in Alzheimer patients. We look forward to providing continued support and insights into your journey for the next phase.
XPro1595 KOL Event
21 Jan 2021 - Phase 1b Trial
NEWS
NEWS
We are proud and very excited to announce that Oxford Brain Diagnostics has been awarded FDA Breakthrough Device Designation for our technology. This is a major step forward to support our efforts in helping clinicians, patients and pharmaceutical companies with tracking and predicting Alzheimer’s disease.
U.S. Food and Drug Administration (FDA) - Breakthrough Device Designation granted for Cortical Disarray Measurement technology.
NEWS
Oxford Brain Diagnostics takes another important step towards the goal of defeating Dementia. The US Patent behind our Cortical Disarray Measurement (CDM®) technology has now been granted. Protection of our unique technology enables us to develop best in class products in the future to support the fight against Alzheimer’s and hopefully other neurological disorders.
obn Awards - Celebrating Innovation & Achievement in Life Sciences
Dr Steven Chance & Dr Mario Torso present three key results using CDM® technology - the relationship between amyloid beta accumulation and cortical architectural change, the impact of sex in whole brain cortical changes in an asymptomatic population, and the classification power of our novel cortical diffusion measurements
AAIC 2020 - Alzheimer’s Association
NEWS
NEWS
Oxford Brain Diagnostics selected as finalists by Nature Research and Merck KGaA. The Spinoff Prize celebrates excellence in original science, innovative application, and business strategy.  As a finalist, OBD and our technology, Cortical Disarray Measurement (CDM®), were featured in a recent issue of Nature.
The Nature magazine Spinoff prize
More
More
More
More
More
More
More
More
NEWS
April 2020 -  Oxford Brain Diagnostics has started a project for Takeda Pharmaceuticals. The Project is testing Cortical Disarray Measurement (CDM®) technology as a neurodegeneration biomarker with a view to using it in future clinical trials.
Assessing CDM® measures in grey matter micro structure in AD Patients for Takeda Pharmaceuticals
More
NEWS
Jan 2020 - Dr Steven Chance, Chief Executive Officer, is invited back to Japan by NHO Neurology Research Group to speak on the role of CDM as a potential clinical tool for the detection of dementia.
National Hospitals Network of Japan
Sept 2019 - Researchers hunt for new dementia detection methods.
Oxford Brain Diagnostics cited in FT Dementia supplement
NEWS
More
NEWS
Apr 2019 - Oxford Brain Diagnostics moves into the heart of Oxford Town centre. We are now located at Oxford Centre for Innovation.
New location